FR14C0041I1 - - Google Patents

Info

Publication number
FR14C0041I1
FR14C0041I1 FR14C0041C FR14C0041I1 FR 14C0041 I1 FR14C0041 I1 FR 14C0041I1 FR 14C0041 C FR14C0041 C FR 14C0041C FR 14C0041 I1 FR14C0041 I1 FR 14C0041I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37215098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0041(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR14C0041I1 publication Critical patent/FR14C0041I1/fr
Application granted granted Critical
Publication of FR14C0041I2 publication Critical patent/FR14C0041I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR14C0041C 2005-04-28 2014-05-19 Derive polycyclique de la carbamoylpyridone a activite inhibitrice sur l'integrase du vih Active FR14C0041I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005131161 2005-04-28
JP2005312076 2005-10-27
PCT/US2006/016604 WO2006116764A1 (en) 2005-04-28 2006-04-28 Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity

Publications (2)

Publication Number Publication Date
FR14C0041I1 true FR14C0041I1 (enrdf_load_html_response) 2014-06-27
FR14C0041I2 FR14C0041I2 (fr) 2015-11-13

Family

ID=37215098

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0041C Active FR14C0041I2 (fr) 2005-04-28 2014-05-19 Derive polycyclique de la carbamoylpyridone a activite inhibitrice sur l'integrase du vih

Country Status (29)

Country Link
US (22) US8129385B2 (enrdf_load_html_response)
EP (9) EP3372281B1 (enrdf_load_html_response)
JP (2) JP4295353B2 (enrdf_load_html_response)
KR (4) KR101848819B1 (enrdf_load_html_response)
AU (1) AU2006239177B8 (enrdf_load_html_response)
BR (1) BRPI0610030B8 (enrdf_load_html_response)
CA (1) CA2606282C (enrdf_load_html_response)
CY (7) CY1115151T1 (enrdf_load_html_response)
DK (6) DK3372281T3 (enrdf_load_html_response)
EA (1) EA014162B1 (enrdf_load_html_response)
ES (7) ES2446324T3 (enrdf_load_html_response)
FI (1) FIC20210017I1 (enrdf_load_html_response)
FR (1) FR14C0041I2 (enrdf_load_html_response)
HK (2) HK1249742A1 (enrdf_load_html_response)
HU (6) HUE044978T2 (enrdf_load_html_response)
IL (4) IL186555A (enrdf_load_html_response)
LT (5) LT3372281T (enrdf_load_html_response)
LU (2) LU92446I2 (enrdf_load_html_response)
MA (1) MA29460B1 (enrdf_load_html_response)
MX (2) MX302718B (enrdf_load_html_response)
NL (2) NL300676I2 (enrdf_load_html_response)
NO (5) NO339525B1 (enrdf_load_html_response)
NZ (1) NZ562339A (enrdf_load_html_response)
PL (5) PL3284520T3 (enrdf_load_html_response)
PT (5) PT3045206T (enrdf_load_html_response)
SI (6) SI2465580T1 (enrdf_load_html_response)
TW (1) TWI378931B (enrdf_load_html_response)
VN (1) VN34404A1 (enrdf_load_html_response)
WO (1) WO2006116764A1 (enrdf_load_html_response)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004031258D1 (de) 2003-12-24 2011-03-10 Biota Scient Management Polycyclische mittel zur behandlung von infektione
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
EP3372281B1 (en) * 2005-04-28 2021-07-07 VIIV Healthcare Company Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
JP4982482B2 (ja) 2005-05-10 2012-07-25 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｉｖインテグラ−ゼ阻害剤
ATE517899T1 (de) 2005-10-04 2011-08-15 Angeletti P Ist Richerche Bio Hiv-integrasehemmer
BRPI0617842A2 (pt) 2005-10-27 2011-08-09 Shionogi & Co composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica
TWI423972B (zh) 2006-09-28 2014-01-21 Biota Scient Management 治療呼吸系融合細胞病毒感染之多環劑
KR20100108337A (ko) 2007-11-15 2010-10-06 베링거 인겔하임 인터내셔날 게엠베하 사람 면역결핍 바이러스 복제의 억제제
WO2009062289A1 (en) 2007-11-15 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
EA019259B1 (ru) 2007-11-16 2014-02-28 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
WO2010011815A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011818A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
HUE020489T4 (hu) 2008-07-25 2016-01-28 Viiv Healthcare Co Dolutegravir elõvegyületek
WO2010011816A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
CN102149385B (zh) * 2008-07-25 2015-04-01 盐野义制药株式会社 化合物
MX2011006241A (es) 2008-12-11 2011-06-28 Shionogi & Co Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios.
KR101682058B1 (ko) * 2008-12-11 2016-12-02 비이브 헬쓰케어 컴퍼니 카르바모일피리돈 ｈｉｖ 인테그라제 억제제를 위한 제조방법 및 중간체
EP2370419B1 (en) 2008-12-11 2017-09-27 Shionogi&Co., Ltd. Maltol ether processes and intermediates
AU2014277831C1 (en) * 2008-12-11 2022-10-06 Shionogi & Co. Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
RS57244B1 (sr) * 2009-06-15 2018-07-31 Shionogi & Co Supstituisani policiklički derivati karbamoilpiridona
WO2011011483A1 (en) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
MX2012004426A (es) 2009-10-13 2012-07-30 Elanco Animal Health Ireland Inhibidores macrociclicos de integrasa.
AU2014202406C1 (en) * 2010-01-27 2019-03-07 Viiv Healthcare Company Antiviral therapy
SG10201707183TA (en) 2010-01-27 2017-10-30 Viiv Healthcare Co Antiviral therapy
AU2014202404C1 (en) * 2010-01-27 2022-06-23 Viiv Healthcare Company Antiviral therapy
TWI508968B (zh) * 2010-02-08 2015-11-21 Biota Scient Management 用於治療呼吸道融合性病毒感染的化合物
EP2540720B1 (en) * 2010-02-26 2015-04-15 Japan Tobacco, Inc. 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
BR112012024796A2 (pt) 2010-04-02 2016-06-07 Janssen R&D Ireland inibidores de integrase macrocíclicos
WO2011129095A1 (ja) * 2010-04-12 2011-10-20 塩野義製薬株式会社 インテグラーゼ阻害活性を有するピリドン誘導体
WO2012006104A2 (en) 2010-06-28 2012-01-12 Academia Sinica, Taiwan Compounds and methods for treating tuberculosis infection
SI3456721T1 (sl) 2010-08-05 2021-05-31 Shionogi & Co., Ltd Postopek izdelave spojin, ki imajo HIV integraza-inhibitorno aktivnost
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
CN103228653B (zh) * 2010-09-24 2016-03-16 盐野义制药株式会社 被取代的多环性氨基甲酰基吡啶酮衍生物的前药
US8796303B2 (en) 2010-11-26 2014-08-05 Biota Scientific Management Pty Ltd. Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections
US20140213553A1 (en) * 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
EP2742051B1 (en) 2011-09-14 2016-10-12 Mapi Pharma Limited Amorpous form of the dolutegravir sodium salt
WO2013054862A1 (ja) * 2011-10-12 2013-04-18 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
EP3141542B1 (en) 2011-12-28 2020-05-27 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
ES2790358T3 (es) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
WO2014099586A1 (en) * 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
EA030003B1 (ru) * 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
PE20151063A1 (es) 2012-12-27 2015-08-03 Japan Tobacco Inc DERIVADO SUSTITUIDO DE ESPIROPIRIDO[1,2-a]PIRAZINA Y USO MEDICO DEL MISMO COMO INHIBIDOR DE LA INTEGRASA DEL VIH
EP2767272A1 (en) 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
WO2014125124A1 (en) 2013-02-18 2014-08-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
US9573965B2 (en) 2013-02-19 2017-02-21 Aurobindo Pharma Ltd Process for the preparation of Dolutegravir
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG11201507453VA (en) 2013-03-15 2015-10-29 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
EA034922B1 (ru) 2013-03-15 2020-04-07 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CA2903022C (en) 2013-03-15 2021-11-09 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
WO2014172188A2 (en) 2013-04-16 2014-10-23 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
WO2014200880A1 (en) * 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2015001572A2 (en) * 2013-07-04 2015-01-08 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
RS56540B1 (sr) * 2013-07-12 2018-02-28 Gilead Sciences Inc Policiklična karbamoilpiridonska jedinjenja i njihova upotreba za lečenje hiv infekcija
NO2865735T3 (enrdf_load_html_response) * 2013-07-12 2018-07-21
WO2015009927A1 (en) 2013-07-17 2015-01-22 Ratiopharm Gmbh Dolutegravir salts
WO2015019310A1 (en) 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof
WO2015039348A1 (en) * 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
EA030695B1 (ru) * 2013-09-27 2018-09-28 Мерк Шарп И Доум Корп. Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015092752A1 (en) 2013-12-20 2015-06-25 Mylan Laboratories Ltd. Novel crystalline form of dolutegravir sodium
WO2015089847A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015108945A2 (en) 2014-01-14 2015-07-23 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2015110897A2 (en) * 2014-01-21 2015-07-30 Laurus Labs Private Limited Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
SG11201510135XA (en) 2014-02-07 2016-01-28 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
WO2015138933A1 (en) 2014-03-13 2015-09-17 Assia Chemical Industries Ltd. Solid state forms of dolutegravir sodium
CN106866701B (zh) * 2014-03-19 2019-03-19 杭州普晒医药科技有限公司 德罗格韦钠盐的晶型及其制备方法
IN2014MU00916A (enrdf_load_html_response) 2014-03-20 2015-09-25 Cipla Ltd
WO2015177537A1 (en) * 2014-05-20 2015-11-26 Cipla Limited Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof
NO2717902T3 (enrdf_load_html_response) * 2014-06-20 2018-06-23
TW201613936A (en) * 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI677489B (zh) * 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
US10011613B2 (en) * 2014-08-22 2018-07-03 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
EP3203995A4 (en) 2014-10-09 2019-05-15 Board of Regents of the University of Nebraska COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3045461A1 (en) 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Processes for preparing dolutegravir and analogues thereof
WO2016125192A2 (en) 2015-02-06 2016-08-11 Mylan Laboratories Limited Process for the preparation of dolutegravir
CZ201599A3 (cs) 2015-02-13 2016-08-24 Zentiva, K.S. Pevné formy solí dolutegraviru a způsob jejich přípravy
WO2016154527A1 (en) * 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
CN110790773A (zh) * 2015-04-02 2020-02-14 吉利德科学公司 多环氨甲酰基吡啶酮化合物及其药物用途
DK4219508T3 (da) * 2015-04-28 2024-08-05 Shionogi & Co Substitueret polycyklisk pyridonderivat og prodrug deraf
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
CZ2015537A3 (cs) 2015-08-04 2017-02-15 Zentiva, K.S. Pevné formy amorfního dolutegraviru
EP3337479B1 (en) 2015-08-19 2023-12-13 Laurus Labs Limited Novel polymorphs of dolutegravir and salts thereof
KR20240095320A (ko) 2015-11-09 2024-06-25 길리애드 사이언시즈, 인코포레이티드 인간 면역결핍 바이러스의 치료를 위한 치료 조성물
EP3377066B1 (en) 2015-11-17 2021-04-07 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
TW201731509A (zh) 2015-12-04 2017-09-16 全球血液治療公司 針對２-羥基-６-（（２-（１-異丙基-１ｈ-吡唑-５-基）吡啶-３-基）甲氧基）-苯甲醛之劑量方案
WO2017106071A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
PT3394069T (pt) 2015-12-21 2019-08-30 Lupin Ltd Processo para a preparação de inibidores de integrase de vih
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
WO2017208105A1 (en) 2016-05-30 2017-12-07 Lupin Limited Novel crystalline form of dolutegravir sodium
ES3035041T3 (en) * 2016-06-23 2025-08-27 Viiv Healthcare Co Compositions and methods for the delivery of therapeutics
ES2952878T3 (es) 2016-08-08 2023-11-06 Hetero Labs Ltd Una composición antirretroviral multiclase
BR112019002132A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composições anti-retrovirais
CN109789144B (zh) * 2016-08-12 2022-04-15 马德拉医疗公司 蛋白激酶调节剂
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
US20190216725A1 (en) * 2016-09-21 2019-07-18 Merck Shapr & Dohme Corp. Drug delivery system for the delivery of integrase inhibitors
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JP2020500866A (ja) 2016-12-02 2020-01-16 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｉｖインテグラーゼ阻害剤として有用な三環式複素環化合物
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
EP3573984A4 (en) 2017-01-26 2020-07-29 Merck Sharp & Dohme Corp. USEFUL SUBSTITUTE QUINOLIZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS
US11040986B2 (en) 2017-02-16 2021-06-22 Sandoz Ag Crystalline forms of cabotegravir sodium
EP3363802B1 (en) 2017-02-16 2019-11-20 Sandoz AG Crystalline form of cabotegravir sodium
JP2020527570A (ja) * 2017-07-18 2020-09-10 ヴィーブ ヘルスケア カンパニー 組み合わせ薬物療法
CA3070319A1 (en) 2017-07-21 2019-01-24 Viiv Healthcare Company Regimens for treating hiv infections and aids
US20210040116A1 (en) 2017-09-07 2021-02-11 Cipla Limited New Polymorphs of Dolutegravir Sodium
CN111386276B (zh) 2017-10-06 2023-06-23 盐野义制药株式会社 制备取代的多环吡啶酮衍生物的立体选择性方法
CA3126348A1 (en) 2018-01-12 2020-07-18 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
WO2019159199A1 (en) 2018-02-16 2019-08-22 Cipla Limited Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
CA3132832A1 (en) 2018-04-09 2019-10-17 Howard E. Gendelman Antiviral prodrugs and formulations thereof
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
MD3805220T2 (ro) 2018-05-31 2024-10-31 Shionogi & Co Derivat policiclic de carbamoilpiridonă
TWI880167B (zh) * 2018-05-31 2025-04-11 日商鹽野義製藥股份有限公司 多環性吡啶并三衍生物
WO2019230857A1 (ja) 2018-05-31 2019-12-05 塩野義製薬株式会社 多環性ピリドン誘導体
ES2975333T3 (es) 2018-07-12 2024-07-04 Laurus Labs Ltd Un proceso para la purificación de derivados policíclicos de carbamoilpiridona protegidos
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
EP4234561A3 (en) 2018-10-22 2023-09-13 Board of Regents of the University of Nebraska Antiviral prodrugs and nanoformulations thereof
US20220175936A1 (en) 2018-11-29 2022-06-09 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof
PT3938047T (pt) 2019-03-22 2022-10-03 Gilead Sciences Inc Compostos de carbamoilpiridona tricíclicos em ponte e seus uso farmacêutico
RU2717101C1 (ru) * 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
WO2021107066A1 (ja) 2019-11-28 2021-06-03 塩野義製薬株式会社 インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬
JP7703538B2 (ja) 2019-12-09 2025-07-07 ヴィーブ、ヘルスケア、カンパニー カボテグラビルを含んでなる医薬組成物
US11697652B2 (en) 2020-02-24 2023-07-11 Gilead Sciences, Inc. Tetracyclic compounds and uses thereof
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2022051198A1 (en) 2020-09-01 2022-03-10 Viiv Healthcare Company Combination of cabotegravir and levonorgestrel
CA3192145A1 (en) 2020-09-30 2022-04-07 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
US20250296988A1 (en) 2020-12-07 2025-09-25 Viiv Healthcare Company Combination therapy
LT4196479T (lt) 2021-01-19 2023-12-11 Gilead Sciences, Inc. Pakeistieji piridotriazino junginiai ir jų panaudojimo būdai
EP4389745A4 (en) * 2021-06-03 2025-10-01 Jiangsu Hengrui Pharmaceuticals Co Ltd PYRIDONE COMPOUND HAVING INTEGRASE INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
US20250034607A1 (en) 2021-12-03 2025-01-30 Viiv Healthcare Company Process of Synthesizing (R)-3-aminobutan-1-ol
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
AU2024209826A1 (en) * 2023-01-18 2025-07-10 Ascletis BioScience Co., Ltd Integrase inhibitor and use thereof
WO2025068912A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions
WO2025068743A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
WO2025128498A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Pharmaceutical compositions
WO2025128496A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Crystalline form
WO2025181723A1 (en) 2024-03-01 2025-09-04 ViiV Healthcare UK (No.3) Limited Dosing regimen

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959316A (en) * 1972-03-13 1976-05-25 Snam Progetti S.P.A. Procedure for propylene oxide synthesis
JPH0296506A (ja) 1988-09-30 1990-04-09 Daicel Chem Ind Ltd 除草剤組成物
JP2533796B2 (ja) 1988-10-18 1996-09-11 ダイセル化学工業株式会社 ５−アルコキシピリジン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2551472B2 (ja) 1988-10-18 1996-11-06 ダイセル化学工業株式会社 ５−アルコキシ−γ−ピロン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
NZ505362A (en) 1997-12-22 2004-12-24 Upjohn Co 4-hydroxyquinoline-3-carboxamides and -hydrazides useful as antiviral agents
WO2001095905A1 (en) † 2000-06-14 2001-12-20 Shionogi & Co., Ltd. Inhibitor for enzyme having two divalent metal ions as active centers
US6580562B2 (en) 2000-07-24 2003-06-17 Yazaki Corporation On-vehicle display unit
US6384263B1 (en) 2000-08-04 2002-05-07 E. I. Du Pont De Nemours And Company Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane
US6919351B2 (en) 2000-10-12 2005-07-19 Merck & Co., Inc. Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors
JP2003032772A (ja) 2001-07-12 2003-01-31 Foster Electric Co Ltd 耳掛け式イヤホン
DK2266958T1 (da) 2001-08-10 2016-04-04 Shionogi & Co Antiviralt middel
GEP20063848B (en) 2001-10-26 2006-06-12 Inst Di Richerche Di Biolog Moltcolare P Angeletti Spa N-substituted hydroxypyrimi-dinone carboxamide inhibitors of hiv integrase
DE60218511T2 (de) 2001-10-26 2007-10-25 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
US7279487B2 (en) 2002-01-17 2007-10-09 Merck & Co., Inc. Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors
AU2003248872A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Hiv integrase inhibitors
EP1541558B1 (en) 2002-08-13 2008-08-13 Shionogi & Co., Ltd. Heterocyclic compounds having hiv integrase inhibitory activity
WO2004024078A2 (en) * 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
NZ540729A (en) 2002-12-27 2008-03-28 Angeletti P Ist Richerche Bio Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds useful as HIV integrase inhibitors
US6960680B2 (en) 2003-01-08 2005-11-01 Rhodia Chirex, Inc. Manufacture of water-soluble β-hydroxynitriles
JP2004244320A (ja) 2003-02-10 2004-09-02 Shionogi & Co Ltd 含窒素複素環抗ウイルス剤
WO2004101512A2 (en) 2003-05-13 2004-11-25 Smithkline Beecham Corporation Naphthyridine integrase inhibitors
AU2003273190A1 (en) * 2003-08-12 2005-02-25 Rachel Beijer Scheduled message service
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP4530642B2 (ja) 2003-10-31 2010-08-25 オリンパス株式会社 内視鏡装置
KR20070002006A (ko) 2004-02-11 2007-01-04 스미스클라인 비참 코포레이션 Ｈｉｖ 인테그라제 억제제
CN1929737A (zh) 2004-03-09 2007-03-14 默克公司 Hiv整合酶抑制剂
US20070161639A1 (en) 2004-03-09 2007-07-12 Philip Jones Hiv integrase inhibitors
WO2005110415A1 (en) 2004-05-07 2005-11-24 Merck & Co., Inc. Hiv integrase inhibitors
EP1973906A1 (en) 2004-12-23 2008-10-01 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
ATE516026T1 (de) 2005-02-21 2011-07-15 Shionogi & Co Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung
AU2006228278C1 (en) 2005-03-31 2011-06-23 Msd Italia S.R.L. HIV integrase inhibitors
EP3372281B1 (en) * 2005-04-28 2021-07-07 VIIV Healthcare Company Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
JP2005312076A (ja) 2005-05-26 2005-11-04 Olympus Corp 電子撮像装置
WO2007019098A2 (en) 2005-08-04 2007-02-15 Smithkline Beecham Corporation Hiv integrase inhibitors
BRPI0617842A2 (pt) 2005-10-27 2011-08-09 Shionogi & Co composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica

Also Published As

Publication number Publication date
US20160207939A1 (en) 2016-07-21
US20160137666A1 (en) 2016-05-19
US20130172559A1 (en) 2013-07-04
NZ562339A (en) 2011-01-28
FR14C0041I2 (fr) 2015-11-13
US8410103B2 (en) 2013-04-02
EA200702080A1 (ru) 2008-04-28
EP1874117A4 (en) 2009-12-30
EP3187225A1 (en) 2017-07-05
NL301109I1 (nl) 2021-09-15
EP2465580B1 (en) 2013-12-18
KR101504998B1 (ko) 2015-03-23
DK3045206T3 (en) 2018-05-22
MX312216B (en) 2013-08-12
PL1874117T3 (pl) 2014-01-31
US11267823B2 (en) 2022-03-08
US8778943B2 (en) 2014-07-15
EP3187225B1 (en) 2022-01-05
US20170267693A1 (en) 2017-09-21
EP3187226A1 (en) 2017-07-05
SI2465580T1 (sl) 2014-04-30
US20190284208A1 (en) 2019-09-19
CY2021016I2 (el) 2021-12-31
NL301109I2 (nl) 2021-09-15
EP1874117B1 (en) 2013-08-28
NO20075165L (no) 2007-11-22
LUC00210I2 (enrdf_load_html_response) 2022-10-07
MX2007013351A (es) 2008-01-21
US20170145033A1 (en) 2017-05-25
HUS2100022I1 (hu) 2021-07-28
HUS2100023I1 (hu) 2021-07-28
LTC1874117I2 (lt) 2025-03-25
SI3284520T1 (sl) 2019-10-30
CY1116331T1 (el) 2017-02-08
SI3187225T1 (sl) 2022-04-29
LTC2465580I2 (enrdf_load_html_response) 2022-10-10
PT3045206T (pt) 2018-07-05
ES2567197T3 (es) 2016-04-20
IL225206A (en) 2017-11-30
NO2017010I1 (no) 2017-03-27
US10927129B2 (en) 2021-02-23
US20170369509A1 (en) 2017-12-28
PT3372281T (pt) 2021-10-14
NL300676I2 (enrdf_load_html_response) 2016-10-11
US20170224695A1 (en) 2017-08-10
KR101363875B1 (ko) 2014-02-21
EP2527007B1 (en) 2016-03-30
US20120115875A1 (en) 2012-05-10
KR20130133061A (ko) 2013-12-05
PT2465580E (pt) 2014-02-25
HUE037795T2 (hu) 2018-09-28
EP2465580A1 (en) 2012-06-20
ES2892304T3 (es) 2022-02-03
WO2006116764A1 (en) 2006-11-02
US9273065B2 (en) 2016-03-01
NO2021018I1 (no) 2021-05-10
MA29460B1 (fr) 2008-05-02
LT3045206T (lt) 2018-06-11
NO339525B1 (no) 2016-12-27
SI1874117T1 (sl) 2014-01-31
ES2667868T3 (es) 2018-05-14
ES2437268T3 (es) 2014-01-09
TW200716635A (en) 2007-05-01
CA2606282C (en) 2016-04-26
ES2667868T5 (es) 2023-06-01
JP2009079058A (ja) 2009-04-16
IL186555A0 (en) 2008-01-20
SI3372281T1 (sl) 2021-11-30
EP3045206B2 (en) 2023-02-15
DK3187225T3 (da) 2022-02-28
US20150232479A1 (en) 2015-08-20
HK1249742A1 (en) 2018-11-09
US8129385B2 (en) 2012-03-06
JP2008540343A (ja) 2008-11-20
PT1874117E (pt) 2013-10-17
LU92446I2 (fr) 2015-10-29
DK3372281T3 (da) 2021-09-27
US20170224694A1 (en) 2017-08-10
IL186555A (en) 2016-10-31
US20140200209A1 (en) 2014-07-17
EP2527007A1 (en) 2012-11-28
PL2465580T3 (pl) 2014-05-30
CA2606282A1 (en) 2006-11-02
JP4295353B2 (ja) 2009-07-15
HUE044978T2 (hu) 2019-11-28
EP3284519A8 (en) 2018-04-18
HK1172282A1 (en) 2013-04-19
KR101580310B1 (ko) 2016-01-04
KR20080009733A (ko) 2008-01-29
EP3284519A1 (en) 2018-02-21
IL225207A (en) 2017-11-30
AU2006239177B2 (en) 2011-10-20
CY2021016I1 (el) 2021-10-15
US20190152990A1 (en) 2019-05-23
KR101848819B1 (ko) 2018-04-16
EP3045206B1 (en) 2018-03-28
LT3372281T (lt) 2021-12-10
EP1874117A1 (en) 2008-01-09
BRPI0610030B8 (pt) 2022-01-11
US9051337B2 (en) 2015-06-09
TWI378931B (en) 2012-12-11
HK1251191A1 (en) 2019-01-25
DK3284520T3 (da) 2019-09-16
KR20140097438A (ko) 2014-08-06
US20220213121A1 (en) 2022-07-07
FIC20210017I1 (fi) 2021-06-10
EP3372281A1 (en) 2018-09-12
HUE056603T2 (hu) 2022-02-28
MX302718B (es) 2012-08-27
CY1124601T1 (el) 2022-07-22
ES2743531T3 (es) 2020-02-19
LTPA2021512I1 (enrdf_load_html_response) 2021-07-12
NO20161315A1 (no) 2007-11-22
EP1874117B8 (en) 2014-03-12
HUS1400039I1 (hu) 2016-08-29
NO340111B1 (no) 2017-03-13
EA014162B1 (ru) 2010-10-29
CY1115151T1 (el) 2015-12-09
PL3045206T3 (pl) 2018-08-31
LTPA2014021I1 (lt) 2014-07-25
EP3284520B1 (en) 2019-06-05
EP3045206A1 (en) 2016-07-20
LT3284520T (lt) 2019-09-25
EP3372281B1 (en) 2021-07-07
US20200339598A1 (en) 2020-10-29
NO2017010I2 (no) 2017-03-27
KR20160003889A (ko) 2016-01-11
BRPI0610030B1 (pt) 2020-09-15
SI3045206T1 (en) 2018-07-31
US20170029438A1 (en) 2017-02-02
ES2446324T3 (es) 2014-03-07
EP3284520A1 (en) 2018-02-21
US20240279238A1 (en) 2024-08-22
ES2906792T3 (es) 2022-04-20
US20170260203A1 (en) 2017-09-14
DK1874117T3 (da) 2013-09-23
IL215788A0 (en) 2011-12-29
CY2014024I1 (el) 2015-12-09
VN34404A1 (en) 2013-07-25
DK2465580T3 (en) 2014-03-10
PL3372281T3 (pl) 2021-12-27
US20090318421A1 (en) 2009-12-24
PT3284520T (pt) 2019-09-10
NO2023042I1 (no) 2023-11-08
US20160304535A1 (en) 2016-10-20
BRPI0610030A2 (pt) 2011-10-11
AU2006239177A1 (en) 2006-11-02
AU2006239177B8 (en) 2012-02-16
CY1122052T1 (el) 2020-10-14
CY1120345T1 (el) 2019-07-10
US20170253616A1 (en) 2017-09-07
US20170209454A1 (en) 2017-07-27
HK1107227A1 (en) 2008-04-03
CY2014024I2 (el) 2025-05-09
PL3284520T3 (pl) 2020-01-31

Similar Documents

Publication Publication Date Title
NL300676I2 (enrdf_load_html_response)
BE2013C074I2 (enrdf_load_html_response)
BE2012C042I2 (enrdf_load_html_response)
BRPI0601358B8 (pt) Aplicador de clipe cirúrgico
BRPI0601402B8 (pt) Aplicador de grampos cirúrgicos
BR122017004707A2 (enrdf_load_html_response)
BRPI0609157A8 (enrdf_load_html_response)
JP2005187480A5 (enrdf_load_html_response)
BRPI0608519A2 (enrdf_load_html_response)
BR122020005056A2 (enrdf_load_html_response)
AP2140A (enrdf_load_html_response)
BR122016029989A2 (enrdf_load_html_response)
BRPI0604219A (enrdf_load_html_response)
JP2005223321A5 (enrdf_load_html_response)
JP2006049913A5 (enrdf_load_html_response)
DE602006007711D1 (enrdf_load_html_response)
BRPI0618215B8 (enrdf_load_html_response)
JP2006160526A5 (enrdf_load_html_response)
BY2237U (enrdf_load_html_response)
JP2006211555A5 (enrdf_load_html_response)
CN105122969C (enrdf_load_html_response)
CN300726697S (zh) 调料瓶套装(b)
CN300726698S (zh) 调料瓶套装(e)
CN300726592S (zh) 碗用具（双壁式4）
CN300725990S (zh) 鞋帮